TP53 and cancer: Although the TOP2A and ADH1B expressions in both LUAD and LUSC correlated with the patient's gender, age, individual cancer stage, histological subtype, nodal metastasis status, and TP53 mutation status, they demonstrated different effects on LUAD and LUSC patients' survival.